July 20, 2021
July 20, 2021 – The U.S. FDA has approved a new indication for Octagam® 10% [immune globulin intravenous (human)] to treat adult dermatomyositis, a rare inflammatory
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
July 16, 2021
July 16, 2021 – The U.S. FDA has approved an expanded indication for Prograf® (tacrolimus – Astellas Pharma)
July 16, 2021
July 16, 2021 – The U.S. FDA has approved RezurockTM (belumosudil), manufactured by Kadmon Holdings,
to treat chronic graft-versus-host
July 16, 2021
July 16, 2021 – The U.S. FDA has approved VaxneuvanceTM (pneumococcal 15-valent conjugate vaccine –
Merck) for active immunization to prevent invasive disease
July 16, 2021
July 16, 2021 – The U.S. FDA has approved Sanofi’s fexinidazole tablets to treat both stages of sleeping
sickness (human African trypanosomiasis, or HAT) caused by Trypanosoma
July 12, 2021
July 12, 2021 – The U.S. FDA is requiring an expanded black box warning for hydroxyethyl
July 12, 2021
July 12, 2021 – The U.S. FDA has approved a new indication for Janssen’s Darzalex Faspro® (daratumumab/
hyaluronidase-fihj) to be used in combination with pomalidomide
July 9, 2021
July 9, 2021 – The U.S. FDA has approved Kerendia® (finerenone), manufactured by Bayer, to reduce the
risk of sustained eGFR decline